446 related articles for article (PubMed ID: 29282264)
1. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy.
Ge L; Pan B; Song F; Ma J; Zeraatkar D; Zhou J; Tian J
BMJ Open; 2017 Dec; 7(12):e018175. PubMed ID: 29282264
[TBL] [Abstract][Full Text] [Related]
2. Five common tumor biomarkers and CEA for diagnosing early gastric cancer: A protocol for a network meta-analysis of diagnostic test accuracy.
Shen M; Wang H; Wei K; Zhang J; You C
Medicine (Baltimore); 2018 May; 97(19):e0577. PubMed ID: 29742692
[TBL] [Abstract][Full Text] [Related]
3. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
4. CT, MRI, and F-18 FDG PET for the detection of non-small-cell lung cancer (NSCLC): A protocol for a network meta-analysis of diagnostic test accuracy.
Zhang Y; Ni J; Wei K; Tian J; Sun S
Medicine (Baltimore); 2018 Sep; 97(38):e12387. PubMed ID: 30235705
[TBL] [Abstract][Full Text] [Related]
5. Comparison of clinical usefulness of serum Ca125 and CA19-9 in pancreatic adenocarcinoma diagnosis: meta-analysis and systematic review of literature.
Skulimowski A; Durczyński A; Strzelczyk J; Hogendorf P
Biomarkers; 2021 Jun; 26(4):287-295. PubMed ID: 33459070
[TBL] [Abstract][Full Text] [Related]
6. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
7. CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis.
Gui JC; Yan WL; Liu XD
Clin Exp Med; 2014 May; 14(2):225-33. PubMed ID: 23456571
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
10. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
11. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
[TBL] [Abstract][Full Text] [Related]
12. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.
O'Brien DP; Sandanayake NS; Jenkinson C; Gentry-Maharaj A; Apostolidou S; Fourkala EO; Camuzeaux S; Blyuss O; Gunu R; Dawnay A; Zaikin A; Smith RC; Jacobs IJ; Menon U; Costello E; Pereira SP; Timms JF
Clin Cancer Res; 2015 Feb; 21(3):622-31. PubMed ID: 24938522
[TBL] [Abstract][Full Text] [Related]
13. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
14. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis.
Zhang Y; Yang J; Li H; Wu Y; Zhang H; Chen W
Int J Clin Exp Med; 2015; 8(7):11683-91. PubMed ID: 26380005
[TBL] [Abstract][Full Text] [Related]
15. Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer.
Wang WS; Liu LX; Li GP; Chen Y; Li CY; Jin DY; Wang XL
Cancer Prev Res (Phila); 2013 Apr; 6(4):331-8. PubMed ID: 23430754
[TBL] [Abstract][Full Text] [Related]
16. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.
Su SB; Qin SY; Chen W; Luo W; Jiang HX
World J Gastroenterol; 2015 Apr; 21(14):4323-33. PubMed ID: 25892884
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
Kawa S; Tokoo M; Hasebe O; Hayashi K; Imai H; Oguchi H; Kiyosawa K; Furuta S; Homma T
Br J Cancer; 1994 Sep; 70(3):481-6. PubMed ID: 8080734
[TBL] [Abstract][Full Text] [Related]
18. Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer.
Jiang JT; Wu CP; Deng HF; Lu MY; Wu J; Zhang HY; Sun WH; Ji M
World J Gastroenterol; 2004 Jun; 10(11):1675-7. PubMed ID: 15162550
[TBL] [Abstract][Full Text] [Related]
19. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons.
Goh SK; Gold G; Christophi C; Muralidharan V
ANZ J Surg; 2017 Dec; 87(12):987-992. PubMed ID: 28803454
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9.
Forsmark CE; Lambiase L; Vogel SB
Pancreas; 1994 Nov; 9(6):731-4. PubMed ID: 7846016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
